Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes - PubMed (original) (raw)
Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes
C J Punt et al. Cancer Immunol Immunother. 1994 Apr.
Abstract
Cell suspensions from 69 human tumor biopsies and malignant effusions depleted of infiltrating T cells were incubated for 10-14 days with mitomycin-C-treated cells of the transformed T cell line MOT as feeder cells. B lymphocytes proliferated and differentiated as indicated by immunoglobulin (Ig) secretion in the culture supernatants (B cell expansion). Ig was present in culture supernatants of tumor cell suspensions incubated without MOT feeder cells (non-expanded cells), but the addition of MOT feeder cells to these cultures invariably resulted in a significant increase in Ig concentration. While IgG, IgA, and IgM isotypes were all detected in supernatants of both expanded- and non-expanded tumor cell suspensions, the increase in total Ig induced by MOT feeder cells was mainly due to an increase in IgG. Peripheral blood B lymphocytes (PBBL) from 15 cancer patients and 4 healthy individuals were also successfully expanded by the same method. In these it was shown that IgA was the predominant Ig isotype. Using a modified enzyme-linked immunosorbent assay, IgG of 25/36 expansions from tumor cell suspensions showed reactivity with autologous tumor targets, and that from 10/13 expansions reacted with allogeneic tumor targets of the same histological diagnosis. No reactivity was found against tumor targets of different histology. IgG of 4/10 expansions of PBBL from cancer patients showed reactivity with allogeneic tumor targets of the same histology, while no reactivity was demonstrated against tumor targets of different histology. IgG of expanded PBBL from healthy individuals showed no reactivity against tumor targets. This method allows detailed study of the specific humoral antitumor immune response of intratumoral and peripheral blood B lymphocytes in cancer.
Similar articles
- Characteristics and responses of EBV immortalized B cells from periodontal disease patients.
Celenligil H, Ebersole JL. Celenligil H, et al. Oral Dis. 1997 Dec;3(4):262-71. doi: 10.1111/j.1601-0825.1997.tb00052.x. Oral Dis. 1997. PMID: 9643223 - Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer.
Garaud S, Zayakin P, Buisseret L, Rulle U, Silina K, de Wind A, Van den Eyden G, Larsimont D, Willard-Gallo K, Linē A. Garaud S, et al. Front Immunol. 2018 Nov 20;9:2660. doi: 10.3389/fimmu.2018.02660. eCollection 2018. Front Immunol. 2018. PMID: 30515157 Free PMC article. Clinical Trial. - B cells, plasma cells and antibody repertoires in the tumour microenvironment.
Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. Sharonov GV, et al. Nat Rev Immunol. 2020 May;20(5):294-307. doi: 10.1038/s41577-019-0257-x. Epub 2020 Jan 27. Nat Rev Immunol. 2020. PMID: 31988391 Review. - Modulation of B-cell immunoglobulin synthesis by retinoic acid.
Ballow M, Wang W, Xiang S. Ballow M, et al. Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S73-81. doi: 10.1006/clin.1996.0144. Clin Immunol Immunopathol. 1996. PMID: 8811066 Review.
Cited by
- Deceleration of glycometabolism impedes IgG-producing B-cell-mediated tumor elimination by targeting SATB1.
Liu J, Li Y, Lu Z, Gu J, Liang Y, Huang E, Wang Z, Zhang H, Wang L, Zhang D, Yu H, Liu R, Chu Y. Liu J, et al. Immunology. 2019 Jan;156(1):56-68. doi: 10.1111/imm.12998. Epub 2018 Oct 10. Immunology. 2019. PMID: 30171602 Free PMC article. - Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?
Siliņa K, Rulle U, Kalniņa Z, Linē A. Siliņa K, et al. Cancer Immunol Immunother. 2014 Jul;63(7):643-62. doi: 10.1007/s00262-014-1544-9. Epub 2014 Apr 3. Cancer Immunol Immunother. 2014. PMID: 24695950 Free PMC article. Review. - Antibodies to tumor necrosis factor: a component of B cell immune responses with a role in tumor/host interaction.
Barbuto JA, Grimes WJ, Hersh EM. Barbuto JA, et al. Cancer Immunol Immunother. 1995 Jan;40(1):31-6. doi: 10.1007/BF01517233. Cancer Immunol Immunother. 1995. PMID: 7828166 Free PMC article. - Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.
DeNardo DG, Coussens LM. DeNardo DG, et al. Breast Cancer Res. 2007;9(4):212. doi: 10.1186/bcr1746. Breast Cancer Res. 2007. PMID: 17705880 Free PMC article. Review. - Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies.
Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, Takhar P, Geh JL, Healy C, Harries M, Acland KM, Rudman SM, Beavil RL, Blower PJ, Beavil AJ, Gould HJ, Spicer J, Nestle FO, Karagiannis SN. Gilbert AE, et al. PLoS One. 2011 Apr 29;6(4):e19330. doi: 10.1371/journal.pone.0019330. PLoS One. 2011. PMID: 21559411 Free PMC article.
References
- Topalian SL, Rosenberg SA. Adoptive cellular therapy: basic principles. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: Lippincott; 1991. p. 187.
- Hurlimann J, Saraga P. Mononuclear cells infiltrating human mammary carcinomas: immunohistochemical analysis with monoclonal antibodies. Int J Cancer. 1985;35:753. - PubMed
- Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986;95:142. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous